TyrosolNCT06883292
The Effects of Tyrosol and Creatine on Endurance, Strength, and Fatigue Resistance in Healthy Adults
A study testing Tyrosol, Creatine and Resistant Dextrin in people with Tyrosol and Creatine, run by Applied Science & Performance Institute at 1 site in United States.
Trial summary
The purpose of this clinical trial is to look at tyrosol's effects on endurance, strength, and fatigue resistance in humans. Additionally, the combination of tyrosol and creatine monohydrate will also be looked at to determine if there is a cooperative effect from using both together. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Tyrosol, Creatine, Endurance Performance
- What is being tested?
- Tyrosol, Creatine and Resistant Dextrin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Mar 2025to 30 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy males or females aged 18-50
- Currently active (engaged in moderate to vigorous activity at least 2-days per week as defined by the American College of Sports Medicine Guidelines)
- Estimated VO2 max equal to or greater than the 50th percentile of the population norm for age (assessed via ACSM guidelines, 2014). The VO2 max estimation at screening will be obtained by following a non-exercise regression model validated and described by Bradshaw et al. (2005).
- Able to read and write in English
- During the study, agree not to take any other supplements that may increase muscle strength or endurance (e.g. protein formulas, creatine, amino acids, tyrosol or stimulants other than caffeine).
- Females willing to share days menstrual cycle for testing purposes as shifts in hormone levels may, potentially, affect testing
Who cannot join
- Known diagnosis of any cardiovascular, metabolic, endocrine, or renal disease
- Recent musculoskeletal injury (<3-months)
- Recent orthopaedic surgery (<12-months)
- History or current malignancy
- Previous gastrointestinal surgery within the past 12 months
- Regular smoker
Show all 12Show fewer
- Regular drinker (>14 drinks per week)
- Current use (within the past 4 weeks) of creatine supplements
- Current use (within past 3 months) of Tyrosol supplementation
- Current use of dietary supplements that may enhance mitochondrial function, muscle hypertrophy, or muscle strength (e.g. protein formulas, creatine, amino acids, tyrosol, etc.).
- Current use of prescription medications that may influence adaptation to exercise (hormone therapies, peptides, etc.)
- Female subjects who do not test negative on a urine pregnancy test or are lactating.
Trial locations and contacts
1 site in 1 country.
United States1 site
Applied Science & Performance Institute
Tampa, Florida, 33634
About this study
Official title: The Effects of Tyrosol and Creatine on Endurance, Strength, and Fatigue Resistance in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
The purpose of this clinical trial is to look at tyrosol's effects on endurance, strength, and fatigue resistance in humans. Additionally, the combination of tyrosol and creatine monohydrate will also be looked at to determine if there is a cooperative effect from using both together. It will be conducted over a 4-week period to compare the effects of the following substances: 1) tyrosol, 2) a placebo (a look-alike substance that contains no drug), 3) creatine, and 4) a combination containing both creatine and tyrosol. Endurance, strength, and fatigue resistance will be compared between groups through repeated testing (described below).
Participants who pass initial screening will be invited on-site for day one (Visit 1) of testing where they will proceed with a series of tests which will include the following: (1) body composition; (2) cognitive testing; (3) full-body strength testing; (4) grip strength on both hands; (5) muscle power testing; (6 \& 7) Resting blood lactic acid testing followed by 5RM (repetition maximum) bench press, leading to multiple sets of bench press (based on the previous weight) completed to failure, followed by another blood lactic acid reading; (8) a repeat of the muscle power testing; (9) a 1 mile time trial run completed as fast as possible.
After the 4-week supplementation period (~28-34 days), all original measures will be repeated as before in the same order (Visit 2). Approximately 24 hours later (Visit 3) participants will then repeat all physical testing procedures except tests 1, 6, 7, and 8, to determine physical recovery. Additionally, questionnaires for soreness and perceived recovery will also be completed at the beginning of Visit 2 and 3, and again on its own as the only testing event at 48 hours post-Visit 2 (visit 4).
Read the detailed description
This study will be a randomized, double-blind, placebo-controlled trial. It will be conducted over a 4-week intervention investigating the effects of tyrosol (500mg Tyrosol); placebo control (3g resistant dextrin), and two additional groups including creatine alone (3g creatine monohydrate) and a combination group containing both creatine and tyrosol (3g creatine monohydrate + 500mg tyrosol/day). Endurance, strength, and fatigue resistance will be examined through repeated strength and endurance testing as described below.
On day one (Visit 1) of testing, after a minimum 8-hour overnight fast, subjects will proceed with a series of tests in the following successive order: (1) DXA for body composition followed by consumption of a standardized food bar snack and at least a 15-minute break after the snack. After the 15-minute break, subjects will proceed with the following tests: (2) Psychomotor Vigilance Test (PVT); (3) full-body strength measurement using a computerized mid-thigh pull; (4) strength via grip strength on both hands, tested in triplicate using a dynamometer; (5) 2 sets of 2 plyometric push-ups (with the average of each set used as the outcome metric) on a dual ground-reaction force plate, with a 30 seconds rest between sets; (6 \& 7) Resting blood lactate will be measured in duplicate followed by determination of the subject's 5RM (repetition maximum) bench press, which will be used to calculate their 1RM. Subjects will then perform one set of bench at 70% of the calculated 1RM to failure, followed by three sets to failure at 50 % of 1RM with a two-minute rest between all sets. After completion of the last set, another blood lactate reading will be taken (in duplicate) and recorded; (8) subjects will then perform the plyometric push-up protocol one more time to assess the immediate effects of fatigue; (9) subjects will then complete a 1 mile time trial run completed as fast as possible. Rate of Perceived Exertion (RPE) will also be collected during the 1 mile run using Borg RPE scale (Borg, 1982).VO2 max will be estimated from the 1 mile run time, age, gender and BMI, using equations described by Kayihan et al. (2014). Finally, the subjects will repeat the PVT at the end of the session.
After the 4 week supplementation period (approximately 28+6 days), all baseline measures will be repeated in the fasted state, in the same successive order (Visit 2). Approximately 24 hours later (Visit 3) subjects will then repeat all physical testing procedures except tests 1, 6, 7, and 8 (which would exclude DXA, Blood Lactate, Bench Press 5RM and sets to failure, and the second plyometric push-up test) to assess physical recovery between groups. Additionally, likert scales for soreness and perceived recovery will be completed as the first outcome measure just prior to the first PVT exam, at Visit 2 and 3, and again on its own as the only testing event performed at 48 hours post-bout (visit 4). Finally, on post-testing days (Visit 2 and 3), a full dosage of the study treatment will be taken with water, as well as a standardized food bar snack; and will be administered on-site by staff. On visit 2, this supplement will be taken just after completion of the DXA (prior to Likert and PVT); on Visit 3, the treatment will be taken prior to the start of Likert scales and PVT testing. The subjects will wait for at least 15 minutes after the snack and treatment to begin the remaining tests.
- Conditions
- Tyrosol, Creatine, Endurance Performance, Cognition
- Being tested
- Tyrosol, Creatine, Resistant Dextrin
- Keywords
- tyrosol, creatine, muscle strength, muscle endurance, muscle recovery, muscle performance, reaction time
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TyrosolDietary supplement
phenolic compound found in olive oil
CreatineDietary supplement
chemical produced naturally by the body used to rapidly regenerate ATP
Resistant DextrinDietary supplement
A type of soluble dietary fiber that is resistant to digestion in the small intestine. It is a byproduct of the starch hydrolysis process, where starch is broken down into smaller chains of glucose molecules
| Study group | Role | What they receive |
|---|---|---|
| Tyrosol and Creatine | Experimental | creatine and tyrosol (3g creatine monohydrate + 500mg tyrosol/day) administered daily Receives: Dietary Supplement: Tyrosol; Dietary Supplement: Creatine |
| Tyrosol + placebo | Experimental | 500mg Tyrosol (administered daily as 1 capsule, containing 500mg/capsule) + 3g of resistant dextrin powder (placebo) Receives: Dietary Supplement: Tyrosol; Dietary Supplement: Resistant Dextrin |
| Creatine + placebo | Active comparator | 3g Creatine Monohydrate powder + 500mg Resistant dextrin capsules (as 1 capsule, containing 500mg/capsule) (placebo) administered daily Receives: Dietary Supplement: Creatine; Dietary Supplement: Resistant Dextrin |
| placebo + placebo | Placebo comparator | 3g of resistant dextrin powder (placebo) + 500mg Resistant dextrin capsules (administered as 1 capsule, containing 500mg/capsule) (placebo) administered daily Receives: Dietary Supplement: Resistant Dextrin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mid Thigh Pull
Utilizing a pronated clean grip, subjects will be instructed to assume a body position similar to the second pull of the snatch and clean. Once body positioning is stabilized, the subject will be given a countdown. Minimal pre-tension will be allowed to eliminate slack prior to initiation of the IMTP. Each subject will perform two warm-up reps, one at 50% and one at 75% of perceived maximum effort. Thereafter, subjects will complete two maximal IMTPs separated by approximately two minutes of rest. Force kinematics from the IMTP will be collected and recorded using a linear position transducer.
Measured: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)
1-mile run
Participants will complete the 1-mile run time trial on a treadmill. The treadmill allows participants to adjust the speed as needed to maintain their maximal sustainable pace throughout the test. The total time taken to complete the 1 mile will be recorded as the primary performance measure.
Measured: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)
Rate of Perceived Exertion (RPE)
RPE will be collected during the 1 mile run using Borg RPE scale (Borg, 1982). Participants will be asked to select a number on the scale to rate their overall effort. A rating of 6 is said to be no effort (rest) and a rating of 20 is considered to be maximal effort. All perceptual measures will be collected in isolation from other participants to promote accuracy and recorded as arbitrary units (a.u.).
Measured: Performed at 0, 0.25, 0.5, 0.75, and 1.0 miles during the 1-mile run at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)
Grip Strength
Grip strength will be conducted using a digital hand dynamometer (Vernier Lab). The dynamometer is an isometric force sensor (strain gauge amplifier-based) that measures the force applied to its pressure pads. 5-second maximal voluntary contractions are performed on both of the participant's hands, measured in triplicate. With the subject's back supported and straight, 90 degrees of elbow flexion, and 0 degrees of shoulder flexion, participants hold the dynamometer in the palm and secure a comfortable grip. They are then instructed to squeeze with maximum force which will be measured by the Vernier LabQuest® 2 dynamometer and analyzed using Logger Pro software (Version 3.16.2). Average and peak force values will be utilized for study analysis.
Measured: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)
Plyometric Push Up (Force Plate)
The force plate is a platform composed of two force plates that separate the platform into left and a right halves. Each plate contains four force sensors which measure the vertical ground reaction force exerted on the platform. The sensors are connected to a laptop computer and analyzed using the Mechanography GRFP Research Edition® software (version 4.2-b05.53-RES).
For the Plyometric Pushup exercise, subjects will perform two sets of two plyometric push-ups on the force plate. Subjects will assume a push up position with one hand centered on each half of the force plate. Each subject will be given an initiation command by the researcher and then perform two maximal effort plyometric push ups on the force plate, pressing themselves as high as possible into the air on each repetition. Subjects will be given 30sec of rest and then repeat once more. Force curves will be analyzed for peak force, rate of force development, and limb symmetry. Results will be averaged and analyzed.
Measured: Performed 2 times (once before bench press and once after bench press) at baseline (visit 1) and at day 28 (visit 2). AT day 29, this will be performed 1 time (visit 3).
Bench Press 5 repetition maximum (RM)
Subjects will be asked to perform a 5 repetition maximum (RM) lift in order to calculate their 1RM for determination of weight needed for the protocol. They will start with a warm-up consisting of the following: 1 set of 8-10 reps of a light weight of their choosing followed by 1-2 sets of 3-5 reps of progressively heavier weights (~50-70% of self-estimated 1RM). Following a 2-minute rest, subjects will select a weight they feel confident they can do for 5-7 reps but not more than 7 reps (based on warm-up weights). Weight will be increased until the subject is only able to complete 5 reps with good form. This will be their 5RM. For safety, a spotter will always be present for lifts and a set of safety bars will be used as well.
Subject's 1RM will be calculated from this 5RM using the Brzycki formula (Macarilla CT, et.al. 2022) 1RM = W / (1.0278 - 0.0278 × R), where W represents the weight lifted in pounds, and R represents the number of repetitions.
Measured: Performed one time at baseline (visit 1) and at day 28 (visit 2).
Bench Press Repetitions to Failure
After calculating the estimated 1RM from the 5RM, subjects will then perform one set of bench press at 70% of the calculated 1RM to failure, followed by three sets to failure at 50 % of 1RM with a two-minute rest between all sets. Total repetitions for each of these sets will be recorded and will be used to determine fatigue and compared to follow-up Visit 2 performance for fatigue resistance. For safety, a spotter will always be present for lifts and a set of safety bars will be used as well.
Measured: Performed one time at baseline (visit 1) and at day 28 (visit 2).
Secondary outcomes (6)
Body Composition (DXA)
Total and regional body composition will be determined by a whole-body scan on a dual-energy x-ray absorptiometry device (DXA) (Horizon A DXA System, Hologic Inc, Marlborough, MA). Each subject will be scanned by a certified technician, and the digital segmentation will be determined via computer algorithm. Fat-free mass, fat mass, and body fat percentage will be determined for each scan. Calibration will be performed against a phantom prior to testing. The abdominal region will be delineated by an upper horizontal border located at half of the distance between the acromion processes and external end of iliac crests, a lower border determined by the external end of iliac crests and the lateral borders extending to the edge of the abdominal soft tissue. All trunk tissue within this standardized height region will be selected for analysis.
Measured: Performed one time at baseline (visit 1) and at day 28 (visit 2).
Blood Lactate
Blood lactate will be measured using the Nova Biomedical Lacate-Plus meter (Nova Biomedical). The procedure is as follows: Researcher will don protective gloves prior to blood collection; using a finger of subject's choice, the finger will be thoroughly cleaned with an alcohol pad and lanced; with a collection strip inserted into the meter, blood from the lancing will be collected and read by the meter; subject's finger will be cleaned with a sterile gauze and all biohazard material will be disposed of according to local, state and federal biohazard guidelines. 2 meters will be used to collect a duplicate reading. This will be collected before the bench press protocols and then again after.
Measured: Performed one time at baseline (visit 1) and at day 28 (visit 2).
Changes in Psychomotor Vigilance Test
This test measures how quickly and accurately you can respond to simple tasks, like pressing a button when you see a specific symbol. It assesses your reaction time and attention span. Participants are instructed to press the <Spacebar> as fast as possible after a red stopwatch appears on screen. A valid response (response occurs after a stopwatch appears) is followed by reaction time feedback.
Measured: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3), once at the beginning of the session and then again at the end of the session.
Perceived Recovery Status (PRS) Likert Scale
The PRS is a composite scale directly proportional to recovery (Laurent, et al. 2011). Hence, the purpose of the scale will be to assess the participant's recovery from the previous exercise session. Subjects will be informed that having no soreness and a high feeling of recovery is a 10, while extreme soreness and low feelings of recovery, leading to limited ability to function, is defined by a range of 0-3, adequate recovery, with some ability to function, is defined by a range of 4-7, and good recovery, with the ability to function normally, is defined by a range of 8-10.
Measured: Performed at the beginning of Visits 2 and 3 (days 28 and 29) and then as the only outcome for Visit 4 (day 30).
Upper Body Soreness Likert Scale
A 7-point likert scale will be used for upper body muscle soreness, after performing 5 bodyweight pushups (modified for women, standard for men). The likert scale is a validated instrument designed to assess self reported muscle soreness, measured across a 7-point scale. The scale ranges from 0 (no soreness), to 6 (unbearable soreness), and has good validity and reliability (Impellizzeri, F., et al., 2007).
Measured: Performed at the beginning of Visits 2 and 3 (days 28 and 29) and then as the only outcome for Visit 4 (day 30).
Estimated VO2max
The total time taken to complete the 1 mile will be recorded as the primary performance measure. VO2max will be calculated from previously validated equations (Kayihan et al., 2014). This will be calculated at baseline and used to compare to subsequent visit testing for changes in aerobic capacity.
Measured: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2025
- Study start24 Mar 2025
- Primary completion30 Aug 2025
- Study completion30 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for TyrosolStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Applied Science & Performance Institute
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Eric Sikorski, PhD, Principal investigator, Applied Science and Performance Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06883292
- Sponsor's protocol ID
- Pro00084231
- Status last verified
- Sep 2025
- First submitted
- 27 Feb 2025
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Macarilla CT, Sautter NM, Robinson ZP, Juber MC, Hickmott LM, Cerminaro RM, Benitez B, Carzoli JP, Bazyler CD, Zoeller RF, Whitehurst M, Zourdos MC. Accuracy of Predicting One-Repetition Maximum from Submaximal Velocity in The Barbell Back Squat and Bench Press. J Hum Kinet. 2022 Apr 26;82:201-212. doi: 10.2478/hukin-2022-0046. eCollection 2022 Apr.
PubMed 36196346Kayihan G, Ozkan A, Koklu Y, Eyuboglu E, Akca F, Koz M, Ersoz G. Comparative analysis of the 1-mile run test evaluation formulae: assessment of aerobic capacity in male law enforcement officers aged 20-23 years. Int J Occup Med Environ Health. 2014 Apr;27(2):165-74. doi: 10.2478/s13382-014-0237-0. Epub 2014 Feb 12.
PubMed 24519369Bradshaw DI, George JD, Hyde A, LaMonte MJ, Vehrs PR, Hager RL, Yanowitz FG. An accurate VO2max nonexercise regression model for 18-65-year-old adults. Res Q Exerc Sport. 2005 Dec;76(4):426-32. doi: 10.1080/02701367.2005.10599315.
PubMed 16739680Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81.
PubMed 7154893
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Tyrosol and Creatine on Endurance, Strength, and Fatigue Resistance in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
- ClinicalTrials.gov ID
- NCT06883292
- Acronym / sponsor ID
- Pro00084231
- Conditions
- Tyrosol, Creatine, Endurance Performance, Cognition
- Keywords
- tyrosol, creatine, muscle strength, muscle endurance, muscle recovery, muscle performance, reaction time
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Applied Science & Performance InstituteIndustry (pharma, biotech, devices)
- Study start
- 24 Mar 2025 (actual)
- Primary completion
- 30 Aug 2025 (actual)
- Study completion
- 30 Aug 2025 (actual)
- First posted
- 19 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical trial is to look at tyrosol's effects on endurance, strength, and fatigue resistance in humans. Additionally, the combination of tyrosol and creatine monohydrate will also be looked at to determine if there is a cooperative effect from using both together. It will be conducted over a 4-week period to compare the effects of the following substances: 1) tyrosol, 2) a placebo (a look-alike substance that contains no drug), 3) creatine, and 4) a combination containing both creatine and tyrosol. Endurance, strength, and fatigue resistance will be compared between groups through repeated testing (described below).
Participants who pass initial screening will be invited on-site for day one (Visit 1) of testing where they will proceed with a series of tests which will include the following: (1) body composition; (2) cognitive testing; (3) full-body strength testing; (4) grip strength on both hands; (5) muscle power testing; (6 \& 7) Resting blood lactic acid testing followed by 5RM (repetition maximum) bench press, leading to multiple sets of bench press (based on the previous weight) completed to failure, followed by another blood lactic acid reading; (8) a repeat of the muscle power testing; (9) a 1 mile time trial run completed as fast as possible.
After the 4-week supplementation period (~28-34 days), all original measures will be repeated as before in the same order (Visit 2). Approximately 24 hours later (Visit 3) participants will then repeat all physical testing procedures except tests 1, 6, 7, and 8, to determine physical recovery. Additionally, questionnaires for soreness and perceived recovery will also be completed at the beginning of Visit 2 and 3, and again on its own as the only testing event at 48 hours post-Visit 2 (visit 4).
Detailed description
This study will be a randomized, double-blind, placebo-controlled trial. It will be conducted over a 4-week intervention investigating the effects of tyrosol (500mg Tyrosol); placebo control (3g resistant dextrin), and two additional groups including creatine alone (3g creatine monohydrate) and a combination group containing both creatine and tyrosol (3g creatine monohydrate + 500mg tyrosol/day). Endurance, strength, and fatigue resistance will be examined through repeated strength and endurance testing as described below.
On day one (Visit 1) of testing, after a minimum 8-hour overnight fast, subjects will proceed with a series of tests in the following successive order: (1) DXA for body composition followed by consumption of a standardized food bar snack and at least a 15-minute break after the snack. After the 15-minute break, subjects will proceed with the following tests: (2) Psychomotor Vigilance Test (PVT); (3) full-body strength measurement using a computerized mid-thigh pull; (4) strength via grip strength on both hands, tested in triplicate using a dynamometer; (5) 2 sets of 2 plyometric push-ups (with the average of each set used as the outcome metric) on a dual ground-reaction force plate, with a 30 seconds rest between sets; (6 \& 7) Resting blood lactate will be measured in duplicate followed by determination of the subject's 5RM (repetition maximum) bench press, which will be used to calculate their 1RM. Subjects will then perform one set of bench at 70% of the calculated 1RM to failure, followed by three sets to failure at 50 % of 1RM with a two-minute rest between all sets. After completion of the last set, another blood lactate reading will be taken (in duplicate) and recorded; (8) subjects will then perform the plyometric push-up protocol one more time to assess the immediate effects of fatigue; (9) subjects will then complete a 1 mile time trial run completed as fast as possible. Rate of Perceived Exertion (RPE) will also be collected during the 1 mile run using Borg RPE scale (Borg, 1982).VO2 max will be estimated from the 1 mile run time, age, gender and BMI, using equations described by Kayihan et al. (2014). Finally, the subjects will repeat the PVT at the end of the session.
After the 4 week supplementation period (approximately 28+6 days), all baseline measures will be repeated in the fasted state, in the same successive order (Visit 2). Approximately 24 hours later (Visit 3) subjects will then repeat all physical testing procedures except tests 1, 6, 7, and 8 (which would exclude DXA, Blood Lactate, Bench Press 5RM and sets to failure, and the second plyometric push-up test) to assess physical recovery between groups. Additionally, likert scales for soreness and perceived recovery will be completed as the first outcome measure just prior to the first PVT exam, at Visit 2 and 3, and again on its own as the only testing event performed at 48 hours post-bout (visit 4). Finally, on post-testing days (Visit 2 and 3), a full dosage of the study treatment will be taken with water, as well as a standardized food bar snack; and will be administered on-site by staff. On visit 2, this supplement will be taken just after completion of the DXA (prior to Likert and PVT); on Visit 3, the treatment will be taken prior to the start of Likert scales and PVT testing. The subjects will wait for at least 15 minutes after the snack and treatment to begin the remaining tests.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Tyrosol and Creatine | Experimental | Dietary Supplement: Tyrosol, Dietary Supplement: Creatinecreatine and tyrosol (3g creatine monohydrate + 500mg tyrosol/day) administered daily |
| Tyrosol + placebo | Experimental | Dietary Supplement: Tyrosol, Dietary Supplement: Resistant Dextrin500mg Tyrosol (administered daily as 1 capsule, containing 500mg/capsule) + 3g of resistant dextrin powder (placebo) |
| Creatine + placebo | Active comparator | Dietary Supplement: Creatine, Dietary Supplement: Resistant Dextrin3g Creatine Monohydrate powder + 500mg Resistant dextrin capsules (as 1 capsule, containing 500mg/capsule) (placebo) administered daily |
| placebo + placebo | Placebo comparator | Dietary Supplement: Resistant Dextrin3g of resistant dextrin powder (placebo) + 500mg Resistant dextrin capsules (administered as 1 capsule, containing 500mg/capsule) (placebo) administered daily |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Healthy males or females aged 18-50
- Currently active (engaged in moderate to vigorous activity at least 2-days per week as defined by the American College of Sports Medicine Guidelines)
- Estimated VO2 max equal to or greater than the 50th percentile of the population norm for age (assessed via ACSM guidelines, 2014). The VO2 max estimation at screening will be obtained by following a non-exercise regression model validated and described by Bradshaw et al. (2005).
- Able to read and write in English
- During the study, agree not to take any other supplements that may increase muscle strength or endurance (e.g. protein formulas, creatine, amino acids, tyrosol or stimulants other than caffeine).
Key exclusion criteria (12 listed)
- Known diagnosis of any cardiovascular, metabolic, endocrine, or renal disease
- Recent musculoskeletal injury (<3-months)
- Recent orthopaedic surgery (<12-months)
- History or current malignancy
- Previous gastrointestinal surgery within the past 12 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tyrosolphenolic compound found in olive oil | Dietary supplement | Tyrosol + placebo, Tyrosol and Creatine |
| Creatinechemical produced naturally by the body used to rapidly regenerate ATP | Dietary supplement | Creatine + placebo, Tyrosol and Creatine |
| Resistant DextrinA type of soluble dietary fiber that is resistant to digestion in the small intestine. It is a byproduct of the starch hydrolysis process, where starch is broken down into smaller chains of glucose molecules | Dietary supplement | Creatine + placebo, Tyrosol + placebo, placebo + placebo |
Primary outcome
Mid Thigh Pull
Time frame: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)
Utilizing a pronated clean grip, subjects will be instructed to assume a body position similar to the second pull of the snatch and clean. Once body positioning is stabilized, the subject will be given a countdown. Minimal pre-tension will be allowed to eliminate slack prior to initiation of the IMTP. Each subject will perform two warm-up reps, one at 50% and one at 75% of perceived maximum effort. Thereafter, subjects will complete two maximal IMTPs separated by approximately two minutes of rest. Force kinematics from the IMTP will be collected and recorded using a linear position transducer.
1-mile run
Time frame: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)
Participants will complete the 1-mile run time trial on a treadmill. The treadmill allows participants to adjust the speed as needed to maintain their maximal sustainable pace throughout the test. The total time taken to complete the 1 mile will be recorded as the primary performance measure.
Rate of Perceived Exertion (RPE)
Time frame: Performed at 0, 0.25, 0.5, 0.75, and 1.0 miles during the 1-mile run at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)
RPE will be collected during the 1 mile run using Borg RPE scale (Borg, 1982). Participants will be asked to select a number on the scale to rate their overall effort. A rating of 6 is said to be no effort (rest) and a rating of 20 is considered to be maximal effort. All perceptual measures will be collected in isolation from other participants to promote accuracy and recorded as arbitrary units (a.u.).
Grip Strength
Time frame: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)
Grip strength will be conducted using a digital hand dynamometer (Vernier Lab). The dynamometer is an isometric force sensor (strain gauge amplifier-based) that measures the force applied to its pressure pads. 5-second maximal voluntary contractions are performed on both of the participant's hands, measured in triplicate. With the subject's back supported and straight, 90 degrees of elbow flexion, and 0 degrees of shoulder flexion, participants hold the dynamometer in the palm and secure a comfortable grip. They are then instructed to squeeze with maximum force which will be measured by the Vernier LabQuest® 2 dynamometer and analyzed using Logger Pro software (Version 3.16.2). Average and peak force values will be utilized for study analysis.
Plyometric Push Up (Force Plate)
Time frame: Performed 2 times (once before bench press and once after bench press) at baseline (visit 1) and at day 28 (visit 2). AT day 29, this will be performed 1 time (visit 3).
The force plate is a platform composed of two force plates that separate the platform into left and a right halves. Each plate contains four force sensors which measure the vertical ground reaction force exerted on the platform. The sensors are connected to a laptop computer and analyzed using the Mechanography GRFP Research Edition® software (version 4.2-b05.53-RES). For the Plyometric Pushup exercise, subjects will perform two sets of two plyometric push-ups on the force plate. Subjects will assume a push up position with one hand centered on each half of the force plate. Each subject will be given an initiation command by the researcher and then perform two maximal effort plyometric push ups on the force plate, pressing themselves as high as possible into the air on each repetition. Subjects will be given 30sec of rest and then repeat once more. Force curves will be analyzed for peak force, rate of force development, and limb symmetry. Results will be averaged and analyzed.
Bench Press 5 repetition maximum (RM)
Time frame: Performed one time at baseline (visit 1) and at day 28 (visit 2).
Subjects will be asked to perform a 5 repetition maximum (RM) lift in order to calculate their 1RM for determination of weight needed for the protocol. They will start with a warm-up consisting of the following: 1 set of 8-10 reps of a light weight of their choosing followed by 1-2 sets of 3-5 reps of progressively heavier weights (~50-70% of self-estimated 1RM). Following a 2-minute rest, subjects will select a weight they feel confident they can do for 5-7 reps but not more than 7 reps (based on warm-up weights). Weight will be increased until the subject is only able to complete 5 reps with good form. This will be their 5RM. For safety, a spotter will always be present for lifts and a set of safety bars will be used as well. Subject's 1RM will be calculated from this 5RM using the Brzycki formula (Macarilla CT, et.al. 2022) 1RM = W / (1.0278 - 0.0278 × R), where W represents the weight lifted in pounds, and R represents the number of repetitions.
Bench Press Repetitions to Failure
Time frame: Performed one time at baseline (visit 1) and at day 28 (visit 2).
After calculating the estimated 1RM from the 5RM, subjects will then perform one set of bench press at 70% of the calculated 1RM to failure, followed by three sets to failure at 50 % of 1RM with a two-minute rest between all sets. Total repetitions for each of these sets will be recorded and will be used to determine fatigue and compared to follow-up Visit 2 performance for fatigue resistance. For safety, a spotter will always be present for lifts and a set of safety bars will be used as well.
6 secondary outcomes
Body Composition (DXA)
Time frame: Performed one time at baseline (visit 1) and at day 28 (visit 2).
Blood Lactate
Time frame: Performed one time at baseline (visit 1) and at day 28 (visit 2).
Changes in Psychomotor Vigilance Test
Time frame: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3), once at the beginning of the session and then again at the end of the session.
Perceived Recovery Status (PRS) Likert Scale
Time frame: Performed at the beginning of Visits 2 and 3 (days 28 and 29) and then as the only outcome for Visit 4 (day 30).
Upper Body Soreness Likert Scale
Time frame: Performed at the beginning of Visits 2 and 3 (days 28 and 29) and then as the only outcome for Visit 4 (day 30).
Estimated VO2max
Time frame: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Background: PubMed 36196346Macarilla CT, Sautter NM, Robinson ZP, Juber MC, Hickmott LM, Cerminaro RM, Benitez B, Carzoli JP, Bazyler CD, Zoeller RF, Whitehurst M, Zourdos MC. Accuracy of Predicting One-Repetition Maximum from Submaximal Velocity in The Barbell Back Squat and Bench Press. J Hum Kinet. 2022 Apr 26;82:201-212. doi: 10.2478/hukin-2022-0046. eCollection 2022 Apr.
- Background: PubMed 24519369Kayihan G, Ozkan A, Koklu Y, Eyuboglu E, Akca F, Koz M, Ersoz G. Comparative analysis of the 1-mile run test evaluation formulae: assessment of aerobic capacity in male law enforcement officers aged 20-23 years. Int J Occup Med Environ Health. 2014 Apr;27(2):165-74. doi: 10.2478/s13382-014-0237-0. Epub 2014 Feb 12.
- Background: PubMed 16739680Bradshaw DI, George JD, Hyde A, LaMonte MJ, Vehrs PR, Hager RL, Yanowitz FG. An accurate VO2max nonexercise regression model for 18-65-year-old adults. Res Q Exerc Sport. 2005 Dec;76(4):426-32. doi: 10.1080/02701367.2005.10599315.
- Background: PubMed 7154893Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81.
- Individual participant dataSharing planned: No
Related trials for Tyrosol
Recruiting
The Effects of Tyrosol and Creatine on Exercise Performance and Cognition in Healthy Adults
Tyrosol, Creatine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eric Sikorski, PhD principal investigator
Applied Science and Performance Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tyrosol, Creatine and Resistant Dextrin in people with Tyrosol and Creatine, run by Applied Science & Performance Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mid Thigh Pull (time frame: Performed one time at baseline (visit 1), at day 28 (visit 2), and day 29 (visit 3)). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06883292, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.